Pay close attention to severe adverse effects of tumor necrosis factor blockers

Qingtong Wang, Wei Wei

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Tumor necrosis factor (TNF) blockers are promising therapeutic agents for patients with conventional therapy insensitive inflammatory diseases. Unfortunately, their use has been associated with an increased rate of malignancies, leukemia, psoriasis and other immune diseases. The U. S. Food and Drug Administration (FDA) is requiring stronger warnings in the prescribing information for TNF blockers. Healthcare Professionals should pay close attention to severe adverse effects of TNF blockers and drug safety.

Original languageEnglish (US)
JournalChinese Pharmacological Bulletin
Volume25
Issue number9
StatePublished - Jan 1 2009
Externally publishedYes

Fingerprint

Tumor Necrosis Factor-alpha
Immune System Diseases
Proxy
United States Food and Drug Administration
Psoriasis
Leukemia
Delivery of Health Care
Safety
Therapeutics
Pharmaceutical Preparations
Neoplasms

Keywords

  • Adalimumab
  • Adverse effect
  • Etanercept
  • Infliximab
  • Rational administration
  • Tumor necrosis factor blocker

ASJC Scopus subject areas

  • Pharmacology

Cite this

Pay close attention to severe adverse effects of tumor necrosis factor blockers. / Wang, Qingtong; Wei, Wei.

In: Chinese Pharmacological Bulletin, Vol. 25, No. 9, 01.01.2009.

Research output: Contribution to journalArticle

@article{ab98466e424648e596d957848b8ca0bd,
title = "Pay close attention to severe adverse effects of tumor necrosis factor blockers",
abstract = "Tumor necrosis factor (TNF) blockers are promising therapeutic agents for patients with conventional therapy insensitive inflammatory diseases. Unfortunately, their use has been associated with an increased rate of malignancies, leukemia, psoriasis and other immune diseases. The U. S. Food and Drug Administration (FDA) is requiring stronger warnings in the prescribing information for TNF blockers. Healthcare Professionals should pay close attention to severe adverse effects of TNF blockers and drug safety.",
keywords = "Adalimumab, Adverse effect, Etanercept, Infliximab, Rational administration, Tumor necrosis factor blocker",
author = "Qingtong Wang and Wei Wei",
year = "2009",
month = "1",
day = "1",
language = "English (US)",
volume = "25",
journal = "Chinese Pharmacological Bulletin",
issn = "1001-1978",
publisher = "Institute of Clinical Pharmacology",
number = "9",

}

TY - JOUR

T1 - Pay close attention to severe adverse effects of tumor necrosis factor blockers

AU - Wang, Qingtong

AU - Wei, Wei

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Tumor necrosis factor (TNF) blockers are promising therapeutic agents for patients with conventional therapy insensitive inflammatory diseases. Unfortunately, their use has been associated with an increased rate of malignancies, leukemia, psoriasis and other immune diseases. The U. S. Food and Drug Administration (FDA) is requiring stronger warnings in the prescribing information for TNF blockers. Healthcare Professionals should pay close attention to severe adverse effects of TNF blockers and drug safety.

AB - Tumor necrosis factor (TNF) blockers are promising therapeutic agents for patients with conventional therapy insensitive inflammatory diseases. Unfortunately, their use has been associated with an increased rate of malignancies, leukemia, psoriasis and other immune diseases. The U. S. Food and Drug Administration (FDA) is requiring stronger warnings in the prescribing information for TNF blockers. Healthcare Professionals should pay close attention to severe adverse effects of TNF blockers and drug safety.

KW - Adalimumab

KW - Adverse effect

KW - Etanercept

KW - Infliximab

KW - Rational administration

KW - Tumor necrosis factor blocker

UR - http://www.scopus.com/inward/record.url?scp=72149087945&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72149087945&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:72149087945

VL - 25

JO - Chinese Pharmacological Bulletin

JF - Chinese Pharmacological Bulletin

SN - 1001-1978

IS - 9

ER -